Study investigating the prevalence of primary insomnia responsive to proton pump inhibitor treatment

Study investigating the prevalence of primary insomnia responsive to proton pump inhibitor treatment - proton pump inhibitor treatment for primary insomnia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003626

Enrollment

200

Registered

2010-05-24

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary insomnia

Interventions

Administration of 20mg/day omeprazole placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who need administration of a sleeping medicine for the treatment of insomnia.

Exclusion criteria

Exclusion criteria: Usage of a sleeping medicine in 2 weeks. Cases treated as mental illness. Usage of PPI or H2RA in 2 weeks. With diseases that may influence sleep. Pregnant or lactating women. With allergy to omeprazole etc. Others which attending doctors decide not suitable.

Design outcomes

Primary

Measure	Time frame
Canges of QOLRAD-J, ESS, PSQI	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026